
    
      A total of 75 patients with CP/CPPS were randomized to three groups in open-label: group 1,
      ciprofloxacin; group 2, aceclofenac; and group 3, roxithromycin. The patients were treated
      for 4 weeks and were subsequently followed for 12 weeks. Changes from baseline in the total
      and domain scores of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) were evaluated.
    
  